AstraZeneca, M.D. Anderson sign pain research deal

AstraZeneca and the University of Texas M. D. Anderson Cancer Center are teaming up to study pain caused by cancer chemotherapy, a side effect that often interferes with patients' ability to stick to the treatments. AstraZeneca and M. D. Anderson will attempt to identify the difference between patients who experience little pain and those with severe pain; understanding these variations could present new drug targets. Financial details of the partnership were not disclosed.

According to the press release, "[t]his is the third of several planned new alliances by AstraZeneca with leading academic and research institutions to address unmet medical needs...including Alzheimer's disease, chronic pain and psychiatric illnesses."

- see this release for more

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.